Long-Term Liabilities: The sum of all non-current liabilities.
Xeris Biopharma Holdings, Inc. (XERS) had Long-Term Liabilities of $254.85M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$74.38M |
|
$0.62M |
|
$11.00M |
|
$63.38M |
|
$67.65M |
|
$6.73M |
|
$-6.11M |
|
$0.62M |
|
$0.62M |
|
$0.62M |
|
$0.62M |
|
$0.62M |
|
$0.62M |
|
$6.73M |
|
$10.76M |
|
163.65M |
|
177.62M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$224.02M |
|
$4.95M |
|
$146.17M |
|
$370.19M |
|
$116.20M |
|
$219.47M |
|
|
Long-Term Liabilities |
$254.85M |
$371.05M |
|
$-0.86M |
|
$-114.51M |
|
$-0.86M |
|
165.53M |
|
| Cash Flow Statement Financials | |
$8.58M |
|
$-0.36M |
|
$11.65M |
|
$75.74M |
|
$95.62M |
|
$19.88M |
|
$17.09M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.93 |
|
-- |
|
-- |
|
1.00 |
|
-254.90 |
|
85.22% |
|
9.05% |
|
9.05% |
|
-- |
|
0.83% |
|
0.83% |
|
$8.22M |
|
-- |
|
-- |
|
-- |
|
0.20 |
|
0.16 |
|
1.38 |
|
65.04 |
|
-72.13% |
|
-0.54% |
|
0.17% |
|
0.28% |
|
$-0.01 |
|
$0.05 |
|
$0.05 |
|